This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: Roehm Gmbh Chemische Fabrik. Active years: 1989-1992.
Company Filing History:
Years Active: 1989-1992
Title: Innovations in Pharmacology: The Contributions of Angelika Christner
Introduction
Angelika Christner, an accomplished inventor based in Bickenbach, Germany, has made significant strides in the field of pharmaceutical innovations. With a focus on pteridine derivatives, she has secured two patents that underscore her expertise and commitment to advancing medical science.
Latest Patents
Christner's latest patents revolve around the development of pharmaceutically efficacious pteridine derivatives. One of the prominent patents describes a pteridine compound characterized by a specific formula that incorporates various hydrocarbon groups and functional substituents. The innovative compounds proposed in her patents hold potential for therapeutic applications, highlighting the importance of pteridines in developing effective pharmaceuticals.
Career Highlights
Working at Röhm GmbH Chemische Fabrik, Christner has carved a niche for herself in the pharmaceutical research sector. Her contributions have not only focused on the theoretical aspects of pteridine chemistry but have also emphasized practical applications in medicine. With her scientific acumen, she continues to drive forward modern therapeutic solutions.
Collaborations
Collaboration is key in the field of innovation, and Christner has worked alongside esteemed colleagues such as Ernst Mutschler and Ingrid Hofmann. Their combined expertise has facilitated the advancement of research initiatives that explore the complexities of pteridine compounds and their therapeutic implications.
Conclusion
Angelika Christner represents the embodiment of innovative spirit within the pharmaceutical industry. Her contributions through her patents pave the way for future advancements and exemplify the critical role that inventors play in enhancing healthcare. With her continued work at Röhm GmbH Chemische Fabrik, the future of pteridine therapeutics looks promising.